Target Details
| UniProt AC | P23458 |
|---|---|
| Gene Symbol | JAK1 |
| Protein Name | Tyrosine-protein kinase JAK1 |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF18379 (FERM_F1) PF18377 (FERM_F2) PF17887 (Jak1_Phl) PF07714 (PK_Tyr_Ser-Thr) PF21990 (SH2_1) |
Summary
- Multi-target molecules 8,920
- Clinical molecules 14
- Avg pChEMBL 8.26
KEGG Pathways (28)
- Coronavirus disease - COVID-19
- EGFR tyrosine kinase inhibitor resistance
- Epstein-Barr virus infection
- Hepatitis B
- Hepatitis C
- Herpes simplex virus 1 infection
- Human T-cell leukemia virus 1 infection
- Human cytomegalovirus infection
- Human papillomavirus infection
- Influenza A
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Leishmaniasis
- Measles
- NOD-like receptor signaling pathway
- Necroptosis
- Osteoclast differentiation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Signaling pathways regulating pluripotency of stem cells
- Th1 and Th2 cell differentiation
- Th17 cell differentiation
- Toll-like receptor signaling pathway
- Toxoplasmosis
- Tuberculosis
- Viral carcinogenesis
Associated Diseases (1)
Active Molecules (8,920)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
AIWAMXKDRXZMII
|
10.3 | IC50 | 3 | — | |
AXTDVIWQOAOLOG
|
10.3 | IC50 | 2 | — | |
BMYVGSNMQZIKOG
|
10.3 | IC50 | 2 | — | |
CAGMYACDPWIQDW
|
10.3 | IC50 | 3 | — | |
CCNHWVJXLXJKFD
|
10.3 | IC50 | 3 | — | |
FIEPDBBGKDUSNR
|
10.3 | IC50 | 2 | — | |
FWXJTNOOTLFTHZ
|
10.3 | IC50 | 2 | — | |
GFJZCOSLDIEWGX
|
10.3 | IC50 | 2 | — | |
GKWPRMUJKHEUNS
|
10.3 | IC50 | 2 | — | |
HTTFBRAIXNPVEK
|
10.3 | IC50 | 3 | — | |
KTANGVPPGNDMTF
|
10.3 | IC50 | 3 | — | |
KZBFERTYFCJTEX
|
10.3 | IC50 | 2 | — | |
LOKUADMVMXXXHK
|
10.3 | IC50 | 2 | — | |
NKZDARSZVOPRKB
|
10.3 | IC50 | 3 | — | |
OHQOIXITGAQUAT
|
10.3 | IC50 | 3 | — | |
PPXQRQBDMLIVCB
|
10.3 | IC50 | 2 | — | |
PTOGBIZUKQEYHC
|
10.3 | IC50 | 2 | — | |
RJDFEVIMBGLEBT
|
10.3 | IC50 | 3 | — | |
RWJMCIIGTXCLPG
|
10.3 | IC50 | 2 | — | |
SIZXITCJPWVYEC
|
10.3 | IC50 | 3 | — | |
SSQRGQRRPUZAFS
|
10.3 | IC50 | 2 | — | |
VHLFWQNBFYCMBY
|
10.3 | IC50 | 2 | — | |
VYYRGWITAKWHDR
|
10.3 | IC50 | 2 | — | |
XBUIUOWQSPJTDT
|
10.3 | IC50 | 2 | — | |
YKBZQRXTJNNAKC
|
10.3 | IC50 | 2 | — | |
ZFQPKPKMLYGAEJ
|
10.3 | IC50 | 2 | — | |
ZGNJQOOBOYTFHA
|
10.3 | IC50 | 2 | — | |
ZIVFIOZGFUJVGQ
|
10.3 | IC50 | 2 | — | |
HBOBPFABMCQOIY
|
10.2 | IC50 | 4 | — | |
NTHZPSGORIKDQB
|
10.2 | IC50 | 4 | — | |
AMQJRDKUJJLKCK
|
10.2 | Ki | 4 | — | |
BAHITJWCHBRYNZ
|
10.2 | Ki | 4 | — | |
BPENMBMNYYAYNC
|
10.2 | Ki | 4 | — | |
BVOCKGYWTIFBJM
|
10.2 | IC50 | 2 | — | |
CQVLTKQROAIZOC
|
10.2 | Ki | 2 | — | |
CRSHNKKIZUFOPX
|
10.2 | IC50 | 2 | — | |
FIXODQLYPRSTCO
|
10.2 | Ki | 4 | — | |
FIXODQLYPRSTCO
|
10.2 | Ki | 4 | — | |
FQXJVLSEWHALMZ
|
10.2 | Ki | 2 | — | |
GCNDXXSIOIKPLV
|
10.2 | IC50 | 2 | — | |
GDKZKFJAUFDVQH
|
10.2 | IC50 | 2 | — | |
JLEJGZVOCPVIIQ
|
10.2 | IC50 | 2 | — | |
JLEJGZVOCPVIIQ
|
10.2 | IC50 | 2 | — | |
JLEJGZVOCPVIIQ
|
10.2 | IC50 | 2 | — | |
KZPCATSDOZHYDA
|
10.2 | Ki | 4 | — | |
LEPDKKSIRCQPDJ
|
10.2 | IC50 | 2 | — | |
LKYNKWVSJBBRNP
|
10.2 | Ki | 2 | — | |
MONOVCADVPANKP
|
10.2 | IC50 | 2 | — | |
MSMFJIFJSMKENF
|
10.2 | IC50 | 2 | — | |
MYSFLKGHFISJQR
|
10.2 | IC50 | 2 | — |